OSE IMMUNO (OSE.PA)
FR0012127173 - Common Stock
We assign a fundamental rating of 4 out of 10 to OSE. OSE was compared to 74 industry peers in the Biotechnology industry. OSE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OSE is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OSE has reported negative net income.
OSE had a positive operating cash flow in the past year.
OSE had negative earnings in each of the past 5 years.
OSE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -16.32%, OSE is in line with its industry, outperforming 59.42% of the companies in the same industry.
OSE has a Return On Equity (-28.24%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.32% | ||
| ROE | -28.24% | ||
| ROIC | N/A |
ROA(3y)-21.31%
ROA(5y)-17.25%
ROE(3y)-63.23%
ROE(5y)-44.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OSE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
OSE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OSE has more shares outstanding
OSE has a worse debt/assets ratio than last year.
2.2 Solvency
OSE has an Altman-Z score of 1.61. This is a bad value and indicates that OSE is not financially healthy and even has some risk of bankruptcy.
OSE has a better Altman-Z score (1.61) than 62.32% of its industry peers.
The Debt to FCF ratio of OSE is 0.76, which is an excellent value as it means it would take OSE, only 0.76 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of OSE (0.76) is better than 92.75% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that OSE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.49, OSE is in line with its industry, outperforming 44.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 0.76 | ||
| Altman-Z | 1.61 |
ROIC/WACCN/A
WACC7.14%
2.3 Liquidity
OSE has a Current Ratio of 4.93. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.93, OSE is in the better half of the industry, outperforming 79.71% of the companies in the same industry.
OSE has a Quick Ratio of 4.93. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.93, OSE belongs to the top of the industry, outperforming 81.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.93 |
3. Growth
3.1 Past
The earnings per share for OSE have decreased strongly by -22.67% in the last year.
Looking at the last year, OSE shows a very negative growth in Revenue. The Revenue has decreased by -87.83% in the last year.
OSE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -38.07% yearly.
EPS 1Y (TTM)-22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%456.48%
Revenue 1Y (TTM)-87.83%
Revenue growth 3Y-40.23%
Revenue growth 5Y-38.07%
Sales Q2Q%5980.49%
3.2 Future
Based on estimates for the next years, OSE will show a very strong growth in Earnings Per Share. The EPS will grow by 44.84% on average per year.
OSE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.03% yearly.
EPS Next Y250.83%
EPS Next 2Y79.68%
EPS Next 3Y44.84%
EPS Next 5YN/A
Revenue Next Year289.49%
Revenue Next 2Y75.23%
Revenue Next 3Y64.03%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OSE. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 4.72, the valuation of OSE can be described as very cheap.
Based on the Price/Forward Earnings ratio, OSE is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of OSE to the average of the S&P500 Index (23.99), we can say OSE is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.72 |
4.2 Price Multiples
OSE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. OSE is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.65 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OSE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as OSE's earnings are expected to grow with 44.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y79.68%
EPS Next 3Y44.84%
5. Dividend
5.1 Amount
OSE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSE IMMUNO
EPA:OSE (12/24/2024, 7:00:00 PM)
7.06
+0.05 (+0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.8%
Inst Owner ChangeN/A
Ins Owners24.86%
Ins Owner ChangeN/A
Market Cap154.05M
Analysts82.22
Price Target14.5 (105.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.72 | ||
| P/S | 69.17 | ||
| P/FCF | 2.65 | ||
| P/OCF | 2.64 | ||
| P/B | 1.89 | ||
| P/tB | 4.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.18
EYN/A
EPS(NY)1.5
Fwd EY21.21%
FCF(TTM)2.66
FCFY37.72%
OCF(TTM)2.67
OCFY37.88%
SpS0.1
BVpS3.73
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.32% | ||
| ROE | -28.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 2609.25% |
ROA(3y)-21.31%
ROA(5y)-17.25%
ROE(3y)-63.23%
ROE(5y)-44.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 0.76 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.93 | ||
| Altman-Z | 1.61 |
F-Score5
WACC7.14%
ROIC/WACCN/A
Cap/Depr(3y)10.76%
Cap/Depr(5y)23.92%
Cap/Sales(3y)4.57%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%456.48%
EPS Next Y250.83%
EPS Next 2Y79.68%
EPS Next 3Y44.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-87.83%
Revenue growth 3Y-40.23%
Revenue growth 5Y-38.07%
Sales Q2Q%5980.49%
Revenue Next Year289.49%
Revenue Next 2Y75.23%
Revenue Next 3Y64.03%
Revenue Next 5YN/A
EBIT growth 1Y-27.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1601.8%
EBIT Next 3Y136.23%
EBIT Next 5YN/A
FCF growth 1Y1111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1213.07%
OCF growth 3YN/A
OCF growth 5YN/A